EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Modified Histopathological Grading Optimizes Prediction of Survival Outcomes in Small Intestinal Neuroendocrine Tumors

Kosmas Daskalakis iD, Marina Tsoli, Göran Wallin, Angelika Kogut, Raj Srirajaskanthan, Christopher Harlow, Georgios Giovos, Martin O Weickert, Beata Kos-Kudla, Gregory Kaltsas

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae111 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Kosmas Daskalakis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, Sweden. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Intestinal Neoplasms, Ki-67 Antigen, Neoplasm Grading. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

One of the major prognostic indices in neuroendocrine tumors (NETs) is Ki67 proliferation index.

Objective

To identify optimal grading Ki67 cutoffs to delineate differences in prognosis of patients with small intestinal NETs (SI-NETs).

Methods

Multicenter retrospective cohort analysis of 551 SI-NET patients diagnosed from 1993 through 2021 at 5 European referral centers with a mean (±SD) follow-up time of 51.5 (±52.9) months, measuring rates of overall survival (OS) and event-free survival (EFS).

Results

Median age at baseline was 62.3 (range, 17-90) years; 252 (45.7%) patients were female. All SI-NETs were well-differentiated, with 326 being grade 1 (G1; 59.2%), 169 G2 (30.7%), and 8 G3 (1.5), while 48 tumors were unspecified grade (8.7%). The median Ki67 was 2% (range, 1%-70%). At baseline, 247 (44.8%) patients had distant metastases (stage IV), 217 locoregional disease (41.1%; stage III), while 29 (7.1%) and 25 (4.5%) presented at stages II and I, respectively. Median OS was 214.7 (95% CI, 152.7-276.6) months and median EFS was 79.8 (68.2-91.5) months. In multivariable Cox-regression OS analysis, the proposed modified histopathological Ki67 grading system (Ki67 5%-10% group: HR = 2.2 [95% CI, 1.15-4.31], P = .018 and Ki67 ≥ 10% group: HR = 5.11 [2.87-9.09], P < .001), age (HR = 1.07 [1.04-1.09], P < .001), Charlson Comorbidity Index (HR = 1.08 [1-1.16], P = .028), and TNM stage (HR = 1.79 [1.05-3.06], P = .034) were independent predictors for death. Pertinent EFS analysis confirmed the proposed modified histopathological Ki67 grading system (Ki67 ≥ 10% group: HR = 4.01 [2.6-6.37], P < .001) and age (HR = 1.04 [1.02-1.05], P < .001) as independent predictors for recurrence, progression, and/or death.

Conclusion

Ki67 proliferation index was a strong and independent predictor of OS and EFS. A modified histopathological grading system applying Ki67 cutoffs of 5% and 10% could be superior to predict differences in SI-NET patient survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsIntestinal NeoplasmsKi-67 AntigenNeoplasm GradingIntestine, SmallHumansFemaleMaleMiddle AgedAdultAgedRetrospective StudiesAged, 80 and overYoung AdultAdolescentPrognosisSurvival RateFollow-Up StudiesBiomarkers, Tumor

Stichwörter der Autor:innen

histopathological gradingsmall intestinal neuroendocrine tumors

Substanzen

Ki-67 AntigenMKI67 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Faculty of Medicine and Health, Örebro University, 703 62 Örebro, Sweden.
  • Second Department of Surgery, "Korgialenio-Benakio," Red Cross General Hospital, 11526 Athens, Greece.
  • Endocrine Oncology Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Endocrinology and Neuroendocrine Neoplasms, Department of Endocrinology and Pathophysiology, Medical University of Silesia, Katowice 40-055, Poland.
  • ENETS Centre of Excellence, Neuroendocrine Tumor Unit, King's College Hospital, London, SE5 9RS, UK.
  • Department of Gastroenterology, King's College Hospital, London, SE5 9RS, UK.

ORCID-Profile: Kosmas Daskalakis

Zitieren

APA

Daskalakis, K., Tsoli, M., Wallin, G., Kogut, A., Srirajaskanthan, R., Harlow, C., Giovos, G., Weickert, M. O., Kos-Kudla, B., & Kaltsas, G. (2024). Modified Histopathological Grading Optimizes Prediction of Survival Outcomes in Small Intestinal Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae111

Vancouver

Daskalakis K, Tsoli M, Wallin G, Kogut A, Srirajaskanthan R, Harlow C, et al. Modified Histopathological Grading Optimizes Prediction of Survival Outcomes in Small Intestinal Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae111

BibTeX
@article{Daskalakis2024,
  author = {Daskalakis, Kosmas and Tsoli, Marina and Wallin, Göran and Kogut, Angelika and Srirajaskanthan, Raj and Harlow, Christopher and Giovos, Georgios and Weickert, Martin O and Kos-Kudla, Beata and Kaltsas, Gregory},
  title = {Modified Histopathological Grading Optimizes Prediction of Survival Outcomes in Small Intestinal Neuroendocrine Tumors},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae111}
}
Kostenlos starten →